Drug Profile
LXI 15029
Alternative Names: LXI15029; SCC-31Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Chinese Academy of Sciences; Fudan University; Shandong Luoxin Pharmaceutical; Shanghai Institute of Materia Medica
- Developer Chinese Academy of Sciences; Shandong Luoxin Pharmaceutical; Shanghai Institute of Materia Medica
- Class Antineoplastics
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease) in China (PO, Capsule)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Breast-cancer(Late-stage disease, Metastatic disease, Monotherapy) in China (PO, Capsule)
- 12 Jun 2017 Phase-I clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (PO) (NCT03125746)